Axsome Therapeutics, Inc.
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as wā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$154.00
Price-3.45%
-$5.50
1Y
Price
Market Cap
$7.878b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-12.6%
EBITDA Margin-14.6%
Net Profit Margin-9.7%
Free Cash Flow Margin-12.6%
EBITDA Margin-14.6%
Net Profit Margin-9.7%
Free Cash Flow MarginRevenue
$638.496m
+65.6%
1y CAGR+183.0%
3y CAGR+137.2%
5y CAGREarnings
-$183.174m
+36.2%
1y CAGR-3.9%
3y CAGR-13.8%
5y CAGREPS
-$3.68
+38.4%
1y CAGR+3.4%
3y CAGR-5.6%
5y CAGRBook Value
$88.295m
$689.805m
Assets$601.510m
Liabilities$241.295m
DebtDebt to Assets
35.0%
-1.4x
Debt to EBITDAFree Cash Flow
-$93.405m
+27.1%
1y CAGR+4.8%
3y CAGR+1.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company